Table 1 Baseline characteristics of treated patients stratified by high vs. low-to-normal inflammatory markers (N = 167)
Baseline characteristics (All patients who were treated with anti-inflammatory agents) | High inflammatory markers group (N = 104) | Low to normal inflammatory markers group (N = 63) | p-value |
|---|---|---|---|
Age (year, median [IQR1 to IQR3]) | 64 [52.5 to 72] | 64 [56 to 74] | 0.609 |
Gender | 0.024 | ||
• Male (%) | 37 (35.6%) | 34 (54%) | |
• Female (%) | 67 (64%) | 29 (46%) | |
Diagnosis of ILD | |||
SARDs | 62 (59.6%) | 34 (54%) | 0.520 |
• SSc (%) | 14 (13.5%) | 6 (9.5%) | 0.624 |
• IIM (%) | 4 (3.9%) | 2 (3.2%) | 1.000 |
• RA (%) | 18 (17.3%) | 12 (19.1%) | 0.836 |
• SLE (%) | 2 (1.9%) | 0 (0%) | 0.527 |
• MCTD (%) | 11 (10.6%) | 3 (4.8%) | 0.254 |
• UCTD (%) | 1 (0.96%) | 4 (6.4%) | 0.068 |
• AsyS (%) | 9 (8.7%) | 2 (3.2%) | 0.211 |
• pSS (%) | 1 (0.96%) | 4 (6.4%) | 0.068 |
• GPA/EGPA (%) | 4 (3.9%) | 3 (4.8%) | 1.000 |
• Overlapped disease (%) | 2 (1.9%) | 2 (3.2%) | 0.633 |
Non-SARDs | 42 (40.4%) | 29 (46%) | 0.520 |
• IPAF (%) | 7 (6.7%) | 7 (11.1%) | 0.391 |
• Fibrotic HP (%) | 13 (12.6%) | 13 (20.6%) | 0.190 |
• Unclassifiable ILD (%) | 23 (22.1%) | 6 (9.5%) | 0.056 |
Underlying other medical history | |||
• GERD (%) | 58 (55.8%) | 33 (52.4%) | 0.749 |
• Pulmonary hypertension (%) | 25 (24%) | 15 (23.8%) | 1.000 |
• OSA (%) | 30 (28.9%) | 12 (19.1%) | 0.198 |
Smoking history | 0.876 | ||
• Non-smoker (%) | 67 (64.4%) | 38 (60.3%) | |
• Former smoker (%) | 36 (34.6%) | 24 (38.1%) | |
• Current smoker (%) | 1 (0.96%) | 1 (1.6%) | |
- Amount of smoking exposure (packyear, median [IQR1 to IQR3]) | 22.5 [11.5 to 38.8] | 15 [11.3 to 24] | 0.229 |
Baseline inflammatory marker level | |||
• ESR (N = 123, median [IQR1 to IQR3]) | 30 [21 to 50] | 7.5 [4 to 14] | < 0.001 |
• CRP (N = 148, median [IQR1 to IQR3]) | 10.9 [7.3 to 22] | 3 [3 to 3] | < 0.001 |
Baseline PFT | |||
• FVC (%predicted, median [IQR1 to IQR3) | 61 [49 to 77] | 64 [51 to 77] | 0.494 |
• DLCO (%predicted, median [IQR1 to IQR3]) | 42.5 [35 to 56] | 48 [35 to 61] | 0.488 |
Meet any PPF criteria (total N = 167) | 40 (38.5%) | 19 (30.2%) | 0.318 |
• PPF by ATS/ERS/JRS/ALAT 2022 (total N = 35) | 26 (25%) | 9 (14.3%) | 0.118 |
- Declined FVC or DLCO with HRCT progression | 10 (38.5%) | 3 (33.3%) | 1.000 |
- Declined FVC or DLCO with worsened symptom | 9 (34.6%) | 1 (11.1%) | 0.235 |
- Worsened symptoms with HRCT progression | 4 (15.4%) | 5 (55.6%) | 0.030 |
- Worsened FVC or DLCO / CT / symptom | 3 (11.5%) | 0 (0%) | 0.553 |
• PF-ILD by INBUILD criteria (total N = 57) | 39 (37.5%) | 18 (28.6%) | 0.312 |
- Declined FVC ≥ 10% | 30 (76.9%) | 11 (61.1%) | 0.341 |
- Declined FVC ≥ 5 with HRCT progression | 4 (10.3%) | 2 (11%) | 1.000 |
- Decline in FVC ≥ 5% with worsened symptoms | 1 (2.6%) | 0 (0%) | 1.000 |
- Worsened symptoms with HRCT progression | 4 (10.3%) | 5 (27.8%) | 0.124 |
Baseline HRCT | |||
• Typical UIP (%) | 34 (32.7%) | 17 (27%) | 0.491 |
• Probable UIP (%) | 62 (59.6%) | 39 (61.9%) | 0.871 |
• Indeterminate UIP (%) | 5 (4.8%) | 2 (3.2%) | 0.711 |
• fNSIP (%) | 4 (3.9%) | 5 (7.9%) | 0.300 |